Analysis of the drug-target-disease network of trichosanthes-angelica sinensis-frankincense-myrrh in the treatment of breast cancer

This study aims to investigate the key bioactive compounds, potential targets, and molecular mechanisms of Trichosanthes-Angelica sinensis-Frankincense-Myrrh (TAFM) in the treatment of breast cancer using network pharmacology and molecular docking methods. The chemical constituents and related targets of TAFM were obtained using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) database. GeneCards, Online Mendelian Inheritance in Man (OMIM), Drugbank, and Therapeutic Target Database (TTD) databases were used to identify breast cancer-related targets. Cytoscape 3.9.1 software and the STRING (Search Tool for the Retrieval of Interaction Gene/Proteins) database were used to visualize the drug component-target-disease and protein interaction networks before screening the core components and key targets. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed using the DAVID (Database for Annotation, Visualization and Integrated Discovery) database, and molecular docking was performed using AutoDock and PyMOL software. We found that the key active ingredients of TAFM in the treatment of breast cancer include β-sitosterol, stigmasterol, ellagic acid, pelargonidin, and petunidin. A total of 38 key targets and hub genes, including ESR1, VEGFA, PTGS2, HSP90AA1, and CASP3, were identified. Molecular docking results confirmed that stigmasterol and Caspase 3 (CASP3) were the most closely related targets. GO enrichment analysis demonstrated that the biological processes involved mainly included drug response, positive apoptosis process regulation, and two-way gene expression regulation. KEGG pathway analysis revealed the involvement of pathways related to cancer, inflammation, and infection-related diseases. The study results provide supportive evidence that β-sitosterol, stigmasterol, ellagic acid, pelargonidin, and petunidin represent the key bioactive ingredients of TAFM that exhibit anti-breast cancer activity through the regulation of estrogen receptor alpha (ESR1), vascular endothelial growth factor A (VEGFA), prostaglandin-endoperoxide synthase 2 (PTGS2), heat shock protein 90 alpha (HSP90AA1), and CASP3 in the treatment of breast cancer.

Molecular docking; Breast cancer; Network pharmacology; Trichosanthes-angelica sinensis-frankincense-myrrh

[1] Coughlin SS. Epidemiology of breast cancer in women. Advances in Experimental Medicine and Biology. 2019; 33: 9–29.

[2] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians. 2021; 71: 209–249.

[3] Li R, Hu X, Shang F, Wu W, Zhang H, Wang Y, et al. Treatment of triple negative breast cancer by near infrared light triggered mild-temperature photothermal therapy combined with oxygen-independent cytotoxic free radicals. Acta Biomaterialia. 2022; 148: 218–229.

[4] Wei Y, Guo Y, Lv S. Research on the progress of traditional chinese medicine components and preparations on histone deacetylase inhibitors—like effects in the course of disease treatment. Journal of Ethnopharmacology. 2022; 296: 115521.

[5] Qu J, Liu Q, You G, Ye L, Jin Y, Kong L, et al. Advances in ameliorating inflammatory diseases and cancers by andrographolide: pharmacokinet-ics, pharmacodynamics, and perspective. Medicinal Research Reviews. 2022; 42: 1147–1178.

[6] Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sciences. 2021; 277: 119504.

[7] Pengbo Wang, Yunyun Dai, Han Dong, Mengyu Yan, Xiaorong Xie. Summary of research on intervention of chinese medicine in breast cancer treatment. Chinese Journal of Experimental Traditional Medical Formulae. 2021; 27: 235–243.

[8] Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. Journal of Cheminformatics. 2014; 6: 13.

[9] Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The genecards suite: from gene data mining to disease genome sequence analyses. Current Protocols in Bioinformatics. 2016; 54: 1.30.1–1.30.33.

[10] Amberger JS, Hamosh A. Searching online mendelian inheritance in man (OMIM): a knowledgebase of human genes and genetic phenotypes. Current Protocols in Bioinformatics. 2017; 58: 1.2.1–1.2.12.

[11] Y. Wang, S. Zhang, F. Li, Y. Zhou, Y. Zhang, Z. Wang, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Research. 2020; 48: D1031–D1041.

[12] Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Research. 2018; 46: D1074–D1082.

[13] Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research. 2019; 47: D607–D613.

[14] Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols. 2009; 4: 44–57.

[15] Burley SK, Berman HM, Bhikadiya C, Bi C, Chen L, Di Costanzo L, et al. RCSB protein data bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy. Nucleic Acids Research. 2019; 47: D464–D474.

[16] Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Research. 2021; 49: D1388–D1395.

[17] Li B, Rui J, Ding X, Yang X. Exploring the multicomponent synergy mechanism of banxia xiexin decoction on irritable bowel syndrome by a systems pharmacology strategy. Journal of Ethnopharmacology. 2019; 233: 158–168.

[18] Liu S, Chuang W, Lam W, Jiang Z, Cheng Y. Safety surveillance of traditional chinese medicine: current and future. Drug Safety. 2015; 38: 117–128.

[19] Deyrup ST, Stagnitti NC, Perpetua MJ, Wong-Deyrup SW. Drug discovery insights from medicinal beetles in traditional Chinese medicine. Biomolecules & Therapeutics. 2021; 29: 105–126.

[20] Song X, Zhang Y, Dai E, Du H, Wang L. Mechanism of action of celastrol against rheumatoid arthritis: a network pharmacology analysis. International Immunopharmacology. 2019; 74: 105725.

[21] Ye J, Li L, Hu Z. Exploring the molecular mechanism of action of yinchen wuling powder for the treatment of hyperlipidemia, using network pharmacology, molecular docking, and molecular dynamics simulation. BioMed Research International. 2021; 2021: 1–14.

[22] Lin Y, Shen C, Wang F, Fang Z, Shen G. Network pharmacology and molecular docking study on the potential mechanism of yi-qi-huo-xue-tong-luo formula in treating diabetic peripheral neuropathy. Journal of Diabetes Research. 2021; 2021: 1–16.

[23] Yousef RG, Ibrahim A, Khalifa MM, Eldehna WM, Gobaara IMM, Mehany ABM, et al. Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, im-munomodulatory, ADMET, toxicity, and molecular dynamic simulation studies. Journal of Enzyme Inhibition and Medicinal Chemistry. 2022; 37: 1389–1403.

[24] V. Kumar, S. Parate, Danishuddin, A. Zeb, P. Singh, G. Lee, et al. 3D-QSAR-based pharmacophore modeling, virtual screening, and molecular dynamics simulations for the identification of spleen tyrosine kinase inhibitors. Frontiers in Cellular and Infection Microbiology. 2022; 12: 909111.

[25] Qayed WS, Hassan MA, El-Sayed WM, Rogério A. Silva J, Aboul-Fadl T. Novel azine linked hybrids of 2-indolinone and thiazolodinone scaffolds as CDK2 inhibitors with potential anticancer activity: in silico design, synthesis, biological, molecular dynamics and binding free energy studies. Bioorganic Chemistry. 2022; 126: 105884.

[26] Manayi A, Saeidnia S, Ostad SN, Hadjiakhoondi A, Ardekani MRS, Vazirian M, et al. Chemical constituents and cytotoxic effect of the main compounds of lythrum salicaria L. Z Naturforsch C J Biosci. 2013; 68: 367–375.

[27] Ervina M, Poerwono H, Widyowati R, Matsunami K, Sukardiman. Bio-selective hormonal breast cancer cytotoxic and antioxidant potencies of Melia azedarach L. wild type leaves. Biotechnology Reports. 2020; 25: e00437.

[28] M.S. Zubair, W.M. Alarif, M.A. Ghandourah, S. Anam. A new steroid glycoside from Begonia sp.: cytotoxic activity and docking studies. Natural Product Research. 2021; 35: 2224–2231.

[29] Awad AB, Chinnam M, Fink CS, Bradford PG. Β-sitosterol activates fas signaling in human breast cancer cells. Phytomedicine. 2007; 14: 747–754.

[30] Y. Ma, G. Li, M. Yu, K. Cao, Q. Li, X. Sun, et al. Anti-lung cancer targets of radix paeoniae rubra and biological molecular mechanism: network pharmacological analyses and experimental validation. OncoTargets and Therapy. 2021; 14: 1925–1936.

[31] H. Bae, G. Song, W. Lim. Stigmasterol causes ovarian cancer cell apoptosis by inducing endoplasmic reticulum and mitochondrial dysfunction. Pharmaceutics. 2020; 12: 488.

[32] Zhang T, Chen H, Wang L, Bai M, Wang Y, Jiang X, et al. Ellagic acid exerts anti-proliferation effects via modulation of tgf-β/smad3 signaling in MCF-7 breast cancer cells. Asian Pacific Journal of Cancer Prevention. 2014; 15: 273–276.

[33] Wang N, Wang Z, Mo S, Loo TY, Wang D, Luo H, et al. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. Breast Cancer Research and Treatment. 2012; 134: 943–955.

[34] Li S, Li W, Wang C, Wu R, Yin R, Kuo H, et al. Pelargonidin reduces the TPA induced transformation of mouse epidermal cells—potential involvement of Nrf2 promoter demethylation. Chemico-Biological Inter-actions. 2019; 309: 108701.

[35] Karthi N, Karthiga A, Kalaiyarasu T, Stalin A, Manju V, Singh SK, et al. Exploration of cell cycle regulation and modulation of the DNA methylation mechanism of pelargonidin: insights from the molecular modeling approach. Computational Biology and Chemistry. 2017; 70: 175–185.

[36] Mudd AM, Gu T, Munagala R, Jeyabalan J, Fraig M, Egilmez NK, et al. Berry anthocyanidins inhibit intestinal polyps and colon tumors by modulation of Src, EGFR and the colon inflammatory environment. Oncoscience. 2021; 8: 120–133.

[37] Wang G, Fu X, Wang J, Guan R, Sun Y, Tony To S. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3‐mediated mitochondrial and PI3K/Akt-MAPK pathway. Journal of Cellular Physiology. 2019; 234: 5888–5903.

[38] Zhang Y, Vareed SK, Nair MG. Human tumor cell growth inhibition by nontoxic anthocyanidins, the pigments in fruits and vegetables. Life Sciences. 2005; 76: 1465–1472.

[39] Kausar H, Jeyabalan J, Aqil F, Chabba D, Sidana J, Singh IP, et al. Berry anthocyanidins synergistically suppress growth and invasive potential of human non-small-cell lung cancer cells. Cancer Letters. 2012; 325: 54–62.

[40] Fowler AM, Salem K, DeGrave M, Ong IM, Rassman S, Powers GL, et al. Progesterone receptor gene variants in metastatic estrogen receptor positive breast cancer. Hormones and Cancer. 2020; 11: 63–75.

[41] Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Research and Treatment. 2010; 123: 725–731.

[42] Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, et al. Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021; 40: 997–1011.

[43] Takahashi T. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-a-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. The EMBO Journal. 2001; 20: 2768–2778.

[44] Sun Z, Li X, Massena S, Kutschera S, Padhan N, Gualandi L, et al. VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd. Journal of Experimental Medicine. 2012; 209: 1363–1377.

[45] Joshi S, Singh AR, Zulcic M, Durden DL. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis. Molecular Cancer Research. 2014; 12: 1520–1531.

[46] V. Condelli, F. Crispo, M. Pietrafesa, G. Lettini, D.S. Matassa, F. Esposito, et al. HSP90 molecular chaperones, metabolic rewiring, and epigenetics: impact on tumor progression and perspective for anticancer therapy. Cells. 2019; 8: 532.

[47] H. Liu, Z. Zhang, Y. Huang, W. Wei, S. Ning, J. Li, et al. Plasma HSP90AA1 predicts the risk of breast cancer onset and distant metastasis. Frontiers in Cell and Developmental Biology. 2021; 9: 639596.

[48] Boland K, Flanagan L, Prehn JH. Paracrine control of tissue regeneration and cell proliferation by Caspase-3. Cell Death & Disease. 2013; 4: e725–e725.

[49] Zhou M, Liu X, Li Z, Huang Q, Li F, Li C. Caspase-3 regulates the migration, invasion and metastasis of colon cancer cells. International Journal of Cancer. 2018; 143: 921–930.

[50] Cheng J, Tian L, Ma J, Gong Y, Zhang Z, Chen Z, et al. Dying tumor cells stimulate proliferation of living tumor cells via caspase-dependent protein kinase Cδ activation in pancreatic ductal adenocarcinoma. Molecular Oncology. 2015; 9: 105–114.

[51] Cheng J, He S, Wang M, Zhou L, Zhang Z, Feng X, et al. The Caspase-3/PKCδ/Akt/VEGF-a signaling pathway mediates tumor repopulation during radiotherapy. Clinical Cancer Research. 2019; 25: 3732–3743.

[52] Harkins LE, Matlaf LA, Soroceanu L, Klemm K, Britt WJ, Wang W, et al. Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae. 2010; 1: 8.

[53] W.H. Teo, H.P. Chen, J.C. Huang, Y.J. Chan. Human cytomegalovirus infection enhances cell proliferation, migration and upregulation of EMT markers in colorectal cancer-derived stem cell-like cells. International Journal of Oncology. 2017; 51: 1415–1426.

[54] J.S. Nam, M. Terabe, M.J. Kang, H. Chae, N. Voong, Y.A. Yang, et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer research. 2008; 68: 3915–3923.